Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis

Future Oncology

Volumn 4, Issue 1, 2008, Pages 23-39

  Berstein, Lev M ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

Aromatase; BRCA1; Endocrine genotoxic liberation and switchings; Estrogen and IGF 1 effects and signaling; Genotoxic type hormonal carcinogenesis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 INDOLEMETHANOL; ANDROGEN RECEPTOR; ANTIGESTAGEN; AROMATASE; AROMATASE INHIBITOR; BRCA1 PROTEIN; CATECHOL DERIVATIVE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; GESTAGEN; GLITAZONE DERIVATIVE; GONADORELIN AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MEVINOLIN; MUTANT PROTEIN; PROGESTERONE RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STEROID; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN;

ANAMNESIS; APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; ENDOCRINOLOGY; ENDOMETRIUM CANCER; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENOTOXICITY; HORMONE METABOLISM; HUMAN; KNOCKOUT GENE; MALIGNANT NEOPLASTIC DISEASE; MUTATIONAL ANALYSIS; NONHUMAN; OVARY CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; STEM CELL; TRANSCRIPTION REGULATION; UBIQUITINATION; WILD TYPE; BREAST TUMOR; CELL TRANSFORMATION; FEMALE; GENETICS; METABOLISM; MUTATION; NEOPLASM; TUMOR SUPPRESSOR GENE;

AROMATASE; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; FEMALE; GENE EXPRESSION REGULATION; GENES, BRCA1; HUMANS; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; RECEPTOR, IGF TYPE 1;

EID: 39549108892     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.1.23     Document Type: Review

References (99)

1. Hall JM, Lee MK, Newman B et al.: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250, 1684-1689 (1990).
2. Miki Y, Swensen J, Shattuck-Eidens D et al.: A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA1. Science 266, 66-71 (1994).
3. Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am. J. Hum. Genet. 57, 1457-14652 (1995).
4. Rubinstein WS: Hereditary breast cancer in Jews. Fam. Cancer 3(3-4), 249-257 (2004).
5. King MC, Marks JK Mandell JB: New York Breast Cancer Study Group: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645), 643-646 (2003).
6. Sokoienko AP, Mitiushkina NV, Buslov KG et al.: High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur. J Cancer. 42 (10), 1380-1384 (2006).
7. Tereschenko IV, Basham VM, Ponder BA, Pharoah PD: BRCA1 and BRCA2 mutations in Russian familial breast cancer: Hum. Mutat. 19(2), 184-185 (2002).
8. Eeles R, Kadourt L: BRCA1/2 carriers and endocrine risk modifiers. Endocr. Relat. Cancer 6, 521-528 (1999).
9. Hohenstein P, Fodde R: Of mice and (wo)men: genotype-phenotype correlations in BRCA1. Human Mol. Genet. 12(2), 271-277 (2003).
10. Thompson D, Easton DF: Breast Cancer Linkage Consortium: cancer incidence in BRCA1 mutation carriers. J. Nad. Cancer Inst. 94, 1358-1365 (2002).
11. Levine DA, Lin O, Barakat RR et al.: Risk of endometrial carrinoma associated with BRCA mutation. Gynecol. Oncol. 80(3), 395-398 (2001).
12. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT: Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. 9, 444-450 (1995).
13. Rosen EM, Fan S, Isaacs C: BRCA1 in hormonal carcinogenesis: basic and clinical research. Endocr Relat. Cancer 12 (3), 533-548 (2005).
14. Hilakivi-Clarke L: Estrogens, BRCA1, and breast cancer. Cancer Res. 60. 4993-5001 (2000).
15. Boulton SJ: Cellular functions of the BRCA tumour-suppressor proteins. Biochem. Soc. Trans. 34(Pt 5), 633-645 (2006).
16. Kinzier KW, Vogelstein B: Cancer-susceptibitity genes. Gatekeepers and caretakers. Nature 386, 761-763 (1997).
17. Welcsh PL, Owens KN, King MC: Insights into the functions of BRCA1 and BRCA2. Trends Genet. 16, 69-74 (2000).
18. Holt JL Thompson ME, Szabo C et al.: Growth retardation and human inhibition by BRCA1 Nat. Genet. 12, 298-302 (1996).
19. Xu J, Fan S, Rosen EM: Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1. Endocrinology 146, 2031-2047 (2005).
20. Ouchi M, Fujiuchj N, Sasai K et al.: BRCA1 phosphorylation by aurora in the regulation of G2 to M transition. J. Biol. Chem. 279, 19643-19648 (2004).
21. Liu S, Ginestier C, Dontu G: BRCA1 regulates human mammary stem cell self-renewal and differentiation. Proceedings of American Association of Cancer Research Annual Meeting, Los Angeles, CA, USA, 14-18 April (2007) (Abstract 5700).
22. Somasundaram K: Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair - perhaps through transcription. J. Cell Biochem. 88(6), 1084-1091 (2003).
23. Scully R, Xie A, Nagaraju G: Molecular functions of BRCA1 in the DNA damage response. Cancer Biol. Ther. 3, 521-527 (2004).
24. Cao L, Xu X, Cao LL et al.: Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogenesis. Carcinogenesis 28(7), 1401-1407 (2007).
25. Kotsopoulos J, Chen Z, Vallis KA, Poll A, Ainsworth P, Narod SA: DNA repair capacity as a possible biornarker of breast cancer risk in female BRCA1 mutation carriers. Br. J. Cancer 96, 118-125 (2007).
26. Rothfuss A, Schutz R, Bochum S et al.: Induced micronucleus frequencies in peripheral lymphocytes a screening test for carriers of BRCA1 mutation in breast cancer farrdites. Cancer Res. 60(2), 390-394 (2000).
27. Fan S, Wang JA, Yuan R et al.: BRCA1 Inhibition of estrogen receptor signaling in transfected cens. Science 284, 1354-1356 (1999).
28. Kawai H, Li H, Chun P, Avraham S, Avraham HK: Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21, 7730-7739 (2002).
29. Fan S, Ma YX Wang C et al.: Role of direct interaction in BRCA1 inhibition of estrogen receptor activity, Oncogene 20, 77-87 (2001).
30. Ma YX, Tomita Y, Fan S et al.: Structural determinants of the BRCA1: estrogen receptor interaction. Oncogene 24, 1831-1846 (2005).
31. Razandi M, Pedram A, Rosen EM, Levin ER. BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol. Cell. Biol. 24, 5900-5913 (2004).
32. Ma Y, Hu C, Riegel AT, Fan S, Rosen EM: Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-α activity. Mol. Endocrinol. 21(8), 1905-1923 (2007).
33. Kennedy RD, Gorski JJ, Quinn JE et al.: BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducibie gene. Cancer Res. 65(22), 10265-10272 (2005).
34. Foulkes WD, Metcalfe K, Sun P et al.: Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological grade. Clin. Cancer Res. 10(6), 2029-2034 (2004).
35. Verhoog LC, Brekelmans CT, Seynaeve C et al.: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351, 316-321: (1998).
36. Sims AH, Howell A, Howell SJ, Clarke RB, Origins of breast cancer subtypes and therapeutic implications. Nat. Clin. Pract. Oncol. 4(9), 516-525 (2007).
37. Moller P, Evans DG, Reis MM et al.: Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int. J. Cancer 121 (5), 1017-1020 (2007).
38. Brekelmans CT, Tlianus-Linthorst MM, Seynaeve C et al.: Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 familles as compared to sporadic breast cancer cases. Eur J. Cancer 43(5), 867-876 (2007).
39. Liehr JG: Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur. J. Cancer Prev. 6, 3-10 (1997).
40. Yue W, Santen RJ, Wang JP et al.: Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J. Steroid Biochem. Mol. Biol. 86(3-5), 477-486 (2003).
41. Berstein LM: Modem concepts of hormonal carcinogenesis: mechanisms, predisposing factors, consequences. In: Hormones, age and cancer. Berstein LM (Ed.). Nauka Publishers, St. Petersburg, Russia, 38-67 (2005).
42. Henderson BE, Feigelson HS: Hormonal carcinogenesis. Carcinogenesis 21(3), 427-433 (2000).
43. Jefcoate CR, Liehr JG, Santen RJ et al.: Tissue-specific synthesis and oxidative metabolism of estrogens. J. Natl. Cancer Inst. Mononographs 27, 95-112 (2000).
44. Cavalieri E, Chakravarti D, Guttenplan J et al.: Catechol estrogen quiriones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta 1766(1), 63-78 (2006).
45. Russo J, Russo IH: The role of estrogen in the initiation of breast cancer. J Steroid Biochem. Mol. Biol. 102 (1-5), 89-96 (2006).
46. Jeffy BD, Hockings JK, Kemp MQ et al.: An estrogen receptor-α/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription. Neoplasia 7 (9), 873-882 (2005).
47. Jernstrom H, Lerman C, Ghadirian P et al.: Pregnancy and risk of breast cancer in carriers of BRCA1 and BRCA2. Lancet 354, 1846-1850 (1999).
48. Bar Sade-Bruchim PB, Khalil T, Quenneville L et al.: Determining the effect of estrogen metabolites on BRCA1- allelic imbalance in normal breast cells heterozygous for BRCA1 mutations. Proceedings of American Association of Cancer Research Annual Meeting. Los Angeles, CA, USA, 14-18 April (2007) (Abstract 3475).
49. Cuendet M, Liu X, Pisha E et al.: Equine estrogen metabolite 4-hydroxyequilenin induces anchorage-independent growth of human mammary epithelial MCF-10A cells: differential gene expression. Mutat. Res. 550(1-2), 109-121 (2004).
50. Bramley M, Clarke RB, Howell A et al.: Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. Br. J Cancer 94 (7), 1021-1028 (2006).
51. Jernström H, Borg K, Olsson H: High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk. Mol. Genet. Metab. 86(1-2), 320-327 (2005).
52. Huo Z, Giger ML, Olopade OI et al.: Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology 225, 519-526 (2002).
53. Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER: Use of alternate promoters to express the aromatase cyochrorne P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J. Clin. Endocrinol. Metab. 81, 3843-3849 (1996).
54. Phillips KW, Goldsworthy SM, Bennett LM, Brownlee HA, Wiseman RW, Davis BJ: Brca1 is expressed independently of hormonal stimulation in the mouse ovary. Lab. Invest. 76, 419-425 (1997).
55. Hu Y, Ghosh S, Amieh A et al.: Modulation of aromatase expression by BRCA1: a possible fink to tissue-specific tumor suppression. Oncogene 24(56), 8343-8348 (2005).
56. Lu M, Chen D, Lin Z et al.: BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibrolasts and malignant epithelial cells. J. Clin. Endocrinol. Metab. 91 (11), 4514-4519 (2006).
57. Ghosh S, Lu Y, Katz A, Hu Y, Li R: Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human-adipose stromal cells. Am J Physiol. Endocrinol. Metab. 292(1), E246-E252 (2007).
58. Chodankar R, Kwang S, Sangiorgi F et al.: Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a ftinctional Brca1 in ovarian granulose cells. Curr. Biol. 15, 561-565 (2005).
59. Park J, Irvine R, Buchanan G et al.: Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor. Cancer Res 60, 5946-5949 (2000).
60. Berns EM, Dirkzwager-Kiel MJ, Kuenen-Bourneester V et al.: Androgen pathway dysregulation in BRCA1-mutated breast tumors. Breast Cancer Res. Treat. 79, 121-127 (2003).
61. Ma Y, Katiyar P, Jones LP et al.: The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol. Endocrinol. 20, 14-34 (2006).
62. King TA, Gemignani ML, Li W et al.: Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers. Cancer Res. 64 (15), 5051-5053 (2004).
63. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenests in mice by a progesterone antagonist. Science 314(5804), 1467-1470 (2006).
64. Maor S, Papa MZ, Yarden RI et al.: Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1. Horm. Metab. Res. 39(3), 179-185 (2007).
65. Shukla V, Coumoul X Can, L et al.: Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members. Cancer Res. 66(14), 7151-7157 (2006).
66. Rzepka-Gorska I, Tarnowski B, Chudecka-Glaz A, Górski B, Zielinska D, Toloczko-Grabarek A: Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res. Treat. 100 (1), 59-63 (2006).
67. Colilia S, Kantoff PW, Neuhausen SL et al.: The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis 27(3), 599-605 (2006).
68. Breast Cancer Family Registry; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (Australasia); Ontario Cancer Genetics Network (Canada): Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years. Breast Cancer Res. Treat. (2007) (Epub ahead of print).
69. Jernström H, Sellberg G, Borg A, Oisson H: Differences in IGFBP-3 regulation between young healthy women from BRCAX families and those belonging to BRCA1/2 families. Eur. J. Cancer Prev. 15(3), 233-241 (2006).
70. Rzepka-Górska I, Tarnowski B, Chudecka-Glaz A, Górski B: BRCA1 mutation, leptin and estrogen levels in breast cancer patients. Eur. J. Gynoecol. Oncol. 26(2), 205-206 (2005).
71. Harvie MN, Bokhari S, Shenton A et al.: Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control study. Fam. Cancer 6(3), 287-294 (2007).
72. Jernström H, Johannsson O, Borg A, Ivarsson H, Oisson H: BRCA1-positive patients are small for gestational age compared with their unaffected relatives. Eur J. Cancer 34(3), 368-371 (1998).
73. Barker DJP: Mothers, babies and health in later life. Churchill Livingstone, Edinburgh-London. UK, 217 (1998).
74. Ozanne SE, Jensen,CB, Tingey KJ, Storgaard H, Madsbad S, Vaag AA: Low birthweight is associated with specific changes in muscle insulin-signalling protein expression. Diabetologia 48(3), 547-552 (2005).
75. Moreau K, Dizin E, Ray H et al.: BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J. Biol. Chem. 281(6), 3172-3181 (2006).
76. Brunet J, Vazquez-Martin A, Colomer R, Graña-Suarez B, Martin-Castillo B, Menendez JA: BRCA1 and acetyl-CoA carboxylase: The metabolic syndrome of breast cancer. Mol. Carcinogenesis (2007) (Epub ahead of print).
77. Henningson M, Bågeman E, Sandberg T, Borg A, Olsson H, Jernström H: Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families. Fam. Cancer 6(4), 445-452 (2007).
78. 't Hart LM, Fritsche A, Rietveld I et al.: Genetic factors and insulin secretion: gene variants in the IGF genes. Diabetes 53(Suppl. 1), 26-30 (2004).
79. Henningson M, Johansson U, Borg A, Oisson H, Jernström H: CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women. Mol. Hum. Reprod. 13(4), 231-236 (2007).
80. Calderon-Margallt R, Paltiel O: Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int. J. Cancer 112(3). 357-364 (2004).
81. Metcalfe K, Lynch HT, Ghadirtan P et al.: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 22, 2328-2335 (2004).
82. Fan S, Meng Q, Auborn K, Carter T, Rosen EM: BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br. J. Cancer 94 (3), 407-426 (2006).
83. Weitzel JN, Buys SS, Shennan WH et al.: Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Clin. Cancer Res. 13(2 Pt 1), 654-658 (2007).
84. Berstein LM: Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett. 224(2), 203-212 (2005).
85. Luo YQ. Mi MT, Wei N, Xu HX, Zhu JD: [Effects of lovastatin on cell cycle distribution in MCF-7 cells transfected with BRCA1] (in Chinese). Ai Zheng 23(8), 924-928 (2004).
86. Marchetti P, Di Rocco CZ, Ricevuto E et al.: Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama. Ann. Oncol. 15 (Suppl. 1), 27-34 (2004).
87. Jones LP, Tilli MT, Assefnia S et al.: Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERα-negative and ERα- positive mammary preneoplasia and cancer. Oncogene (2007) (Epub ahead of print).
88. Lu M, Chen D, Lin Z et al.: BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells. J. Clin. Endocrinol. Metab. 91 (11), 4514-4519 (2006).
89. Berstein LM, Vasilyev DA, Poroshina TE, Kovalenko IG: Glucose-induced effects and joker function of glucose: endocrine or genotoxic prevalence? Horm. Metab. Res. 38(10), 650-655 (2006).
90. Berstein LM, Kovalevskij AY, Poroshina TE et al.: Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: role of menopausal status, estrogens and hyperglycemia. Int J. Cancer 121 (3), 514-519 (2007).
91. Berttein LM. Role of endocrine-genotoxic switchings in cancer and other human diseases: basic triad. In: Innovative Endocrinolov of Cancer. Berstein LM, Santen RJ, (Eds). Landes Bioscience, Austin, TX, USA, 35-51 (2008).
92. Berstein LM, Tsydina, EV, Vasilyev DA, Poroshina TE, Kovalenkc, IG: The phenomenon of the switching of estrogen effects and joker function of glucose: similarities and relation to age-associated pathology and approaches to correction. Ann. NY Acad. Sci. 1057, 235-246 (2005).
93. Lu F, Zahid M, Saeed M, Cavalieri EL, Ragan EG: Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF-10F cells. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin induction and catechol-O-methyltransferase inhibition. J. Steroid Biochem. Mol. Biol. 105(1-5), 150-158 (2007).
94. Wadia, PR, Vandenberg LN, Schaeberle CM, Rubin BS, Sonnenschein C, Soto AM: Perinatal bisphenol A exposure alters estrogen sensitivity of the mammary gland in diverse mouse strains. Environ. Health Perspect. 115(4), 592-598 (2007).
95. Bulun SE, Mahendroo MS, Simpson ER: Polymerase chain reaction amplification fails to detect aromatase cytochrome P450 transcripts in normal human endometrium or decidua. J. Clin Enocrinol Metab. 76 (6), 1458-1463 (1993).
96. Putti TC, El-Rehim DM, Rakha EA et al.: Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod. Pathol. 18(1), 26-35 (2005).
97. Sotgia F, Rui H, Bonuccelli G, Mercier I, Pestell RG, Lisanti MP: Caveolin-1, mammary stern cells, and estrogen-dependent breast cancers. Cancer Res. 66(22), 10647-10651 (2006).
98. Hosey Am, Gorski JJ, Murray MM et al.: Molecular basis for estrogen receptor α deficiency in BRCA1-linked breast dancer. J. Natl Cancer Inst. 99(2 2), 1683-1694 (2007).
99. Jordan VC: Estrogen receptors in BRCA1- mutant breast cancer: now you see them, now you don't. J. Natl Cancer Inst. 99 (22), 1655-1657 (2007).